Legal & General Group Plc Takes $1.45 Million Position in Establishment Labs Holdings Inc. $ESTA

Legal & General Group Plc acquired a new stake in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 16,839 shares of the company’s stock, valued at approximately $1,445,000. Legal & General Group Plc owned about 0.06% of Establishment Labs as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ESTA. KBC Group NV bought a new stake in Establishment Labs in the 1st quarter worth approximately $28,000. Quarry LP bought a new position in shares of Establishment Labs during the 3rd quarter valued at $34,000. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Establishment Labs in the 2nd quarter worth $43,000. Kestra Advisory Services LLC purchased a new position in shares of Establishment Labs in the 4th quarter worth $47,000. Finally, Osaic Holdings Inc. grew its holdings in shares of Establishment Labs by 900.0% in the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after acquiring an additional 1,800 shares during the period. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Stock Performance

NASDAQ:ESTA opened at $74.29 on Monday. The company has a debt-to-equity ratio of 12.11, a quick ratio of 2.52 and a current ratio of 3.84. The stock has a 50-day simple moving average of $83.45 and a two-hundred day simple moving average of $74.89. The firm has a market capitalization of $2.21 billion, a PE ratio of -56.71 and a beta of 1.05. Establishment Labs Holdings Inc. has a 52-week low of $36.53 and a 52-week high of $97.59.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.05). The company had revenue of $67.54 million during the quarter, compared to the consensus estimate of $65.79 million. Establishment Labs had a negative return on equity of 196.69% and a negative net margin of 15.82%.The firm’s quarterly revenue was up 31.7% compared to the same quarter last year. During the same period last year, the business earned ($0.57) EPS. Analysts forecast that Establishment Labs Holdings Inc. will post -1.15 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. TD Cowen upped their price objective on Establishment Labs from $95.00 to $117.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. JPMorgan Chase & Co. raised their target price on Establishment Labs from $84.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Canaccord Genuity Group set a $105.00 price target on Establishment Labs in a research note on Thursday, August 6th. Mizuho upped their price target on shares of Establishment Labs from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Finally, Needham & Company LLC increased their price objective on shares of Establishment Labs from $86.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $100.25.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.